{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:57:26Z","timestamp":1781269046676,"version":"3.54.1"},"reference-count":48,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Courtney\u2019s Courage","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"NIH\/NCI","award":["R01 CA277493 RS & EK"],"award-info":[{"award-number":["R01 CA277493 RS & EK"]}]},{"name":"PANDA","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"University of Arizona Cancer Center Support","award":["P30 CA023074"],"award-info":[{"award-number":["P30 CA023074"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,5,23]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Relapse and graft-versus-host disease (GvHD) remain primary causes of treatment failure in patients with B-cell acute lymphoblastic leukemia (B-ALL) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). While abatacept (ABATA) effectively mitigates GvHD via CD28-costimulation blockade, there is significant concern that it concurrently diminishes graft-versus-leukemia (GvL) effects, potentially leading to higher relapse rates. We investigated whether blinatumomab (BLINA) retains antileukemic efficacy in the presence of ABATA using in vitro assays and humanized NOD.Cg-Prkdc\n                      <jats:sup>scid<\/jats:sup>\n                      Il2rg\n                      <jats:sup>tm1Wjl<\/jats:sup>\n                      Tg(IL15)1Sz\/SzJ (NSG-IL15) and NOD.Cg-Prkdc\n                      <jats:sup>scid<\/jats:sup>\n                      Il2rg\n                      <jats:sup>tm1Wjl<\/jats:sup>\n                      \/SzJ (NSG) mouse models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In vitro and ex vivo flow cytometry-based cytotoxicity, degranulation (CD107a), cytokine production (interferon (IFN)-\u03b3), and activation-marker (CD25, CD69, CD137, OX40) assays were performed using healthy donor peripheral blood mononuclear cells (PBMCs) (pretreated\u00b1ABATA) against leukemia or lymphoma cell lines (RS4;11, NALM-6, and JEKO-1) in the presence or not of BLINA. In vivo human PBMC-reconstituted NSG-IL-15 mice bearing RS4;11 B-ALL xenografts were treated with vehicle, monotherapy (BLINA or ABATA), or combination therapy. Leukemia burden and immune reconstitution were assessed through week 4; GvHD scores and overall survival were monitored longitudinally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ABATA did not impair BLINA-mediated cytotoxicity across multiple effector-to-target ratios against any of the cell lines, nor did it reduce BLINA-induced degranulation, IFN-\u03b3 production, or activation marker expression. In vivo, BLINA monotherapy significantly reduced leukemia burden, but resulted in early mortality due to severe GvHD. Conversely, ABATA markedly reduced GvHD severity. The combination of BLINA and ABATA preserved potent antileukemic efficacy while significantly extending median survival by 35 days compared with tumor controls (p&lt;0.0001). Although ABATA attenuated T-cell expansion and differentiation, BLINA-driven cytotoxic function was maintained, even after prolonged in vivo exposure to cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA-4-Ig).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings provide preclinical proof-of-concept that BLINA and ABATA can be combined to uncouple GvL from GvHD. This strategy preserves CD28-independent T-cell cytotoxicity while limiting allo-reactivity, providing a strong rationale for investigating this combination in the post-transplant setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-014890","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:10:24Z","timestamp":1781266224000},"page":"e014890","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03849651","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07254793","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07105579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07052370","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-890X","authenticated-orcid":false,"given":"Geovana S F","family":"Leite","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The University of Arizona College of Medicine Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sullivan","sequence":"additional","affiliation":[{"name":"School of Nutritional Sciences and Wellness, University of Arizona, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-6889","authenticated-orcid":false,"given":"Dimitrios","family":"Filioglou","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Arizona College of Medicine Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matina","family":"Kounelis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Arizona College of Medicine Tucson, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Batatinha","sequence":"additional","affiliation":[{"name":"School of Nutritional Sciences and Wellness, University of Arizona, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-6881","authenticated-orcid":false,"given":"Richard J","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Arizona College of Medicine Tucson, Tucson, Arizona, USA"},{"name":"School of Nutritional Sciences and Wellness, University of Arizona, Tucson, Arizona, USA"},{"name":"The University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-6965","authenticated-orcid":false,"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Arizona College of Medicine Tucson, Tucson, Arizona, USA"},{"name":"The University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026061205101439000_14.6.e014890.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02395-4"},{"key":"2026061205101439000_14.6.e014890.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004043"},{"key":"2026061205101439000_14.6.e014890.3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17474086.2023.2273847","article-title":"The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Maurer","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"2026061205101439000_14.6.e014890.4","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1194891","article-title":"Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases","volume":"11","author":"Zaidman","year":"2023","journal-title":"Front Pediatr"},{"key":"2026061205101439000_14.6.e014890.5","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.796994","article-title":"Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?","volume":"10","author":"Rozmus","year":"2022","journal-title":"Front Pediatr"},{"key":"2026061205101439000_14.6.e014890.6","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1158\/1078-0432.CCR-25-0688","article-title":"FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD","volume":"31","author":"Norsworthy","year":"2025","journal-title":"Clinical Cancer Research"},{"key":"2026061205101439000_14.6.e014890.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.003"},{"key":"2026061205101439000_14.6.e014890.8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/bloodadvances.2021005208","article-title":"Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation","volume":"6","author":"Qayed","year":"2022","journal-title":"Blood Adv"},{"key":"2026061205101439000_14.6.e014890.9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01086"},{"key":"2026061205101439000_14.6.e014890.10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404661121","article-title":"Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy","volume":"121","author":"Mok","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026061205101439000_14.6.e014890.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0669"},{"key":"2026061205101439000_14.6.e014890.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411680"},{"key":"2026061205101439000_14.6.e014890.13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005579"},{"key":"2026061205101439000_14.6.e014890.14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1956125","article-title":"Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?","volume":"10","author":"Pariury","year":"2021","journal-title":"Oncoimmunology"},{"key":"2026061205101439000_14.6.e014890.15","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/bmt.2017.186","article-title":"Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation","volume":"52","author":"Zeng","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2026061205101439000_14.6.e014890.16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082248"},{"key":"2026061205101439000_14.6.e014890.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.06.006"},{"key":"2026061205101439000_14.6.e014890.18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41409-022-01846-9","article-title":"Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC","volume":"58","author":"Chauvet","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2026061205101439000_14.6.e014890.19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2018-0104","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review","volume":"11","author":"Durer","year":"2019","journal-title":"Immunotherapy"},{"key":"2026061205101439000_14.6.e014890.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013290"},{"key":"2026061205101439000_14.6.e014890.21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216105","article-title":"Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation","volume":"24","author":"Mancusi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026061205101439000_14.6.e014890.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070051","article-title":"Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed\/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I\u2013II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21)","volume":"13","author":"Sakaguchi","year":"2023","journal-title":"BMJ Open"},{"key":"2026061205101439000_14.6.e014890.23","doi-asserted-by":"crossref","DOI":"10.1177\/2040620721994348","article-title":"Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma","volume":"12","author":"Smith","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"2026061205101439000_14.6.e014890.24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2026061205101439000_14.6.e014890.25","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltaf025","article-title":"Cytokine-induced memory-like NK cells combined with Tafasitamab demonstrate efficacy against B-cell acute lymphoblastic leukemia","volume":"5","author":"Filioglou","year":"2025","journal-title":"Immunother Adv"},{"key":"2026061205101439000_14.6.e014890.26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.2023023660","article-title":"Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation","volume":"144","author":"Kean","year":"2024","journal-title":"Blood"},{"key":"2026061205101439000_14.6.e014890.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01101-z"},{"key":"2026061205101439000_14.6.e014890.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33018-1"},{"key":"2026061205101439000_14.6.e014890.29","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.beha.2023.101485","article-title":"The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia","volume":"36","author":"Prockop","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026061205101439000_14.6.e014890.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S274551","article-title":"Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions","volume":"16","author":"Varadarajan","year":"2023","journal-title":"Onco Targets Ther"},{"key":"2026061205101439000_14.6.e014890.31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/cei.13659","article-title":"Cytotoxic T lymphocyte antigen-4 regulates development of xenogenic graft versus host disease in mice via modulation of host immune responses induced by changes in human T cell engraftment and gene expression","volume":"206","author":"Gao","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"2026061205101439000_14.6.e014890.32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"2026061205101439000_14.6.e014890.33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96378","article-title":"Selective CD28 blockade attenuates CTLA-4\u2013dependent CD8+ memory T cell effector function and prolongs graft survival","volume":"3","author":"Liu","year":"2018","journal-title":"JCI Insight"},{"key":"2026061205101439000_14.6.e014890.34","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405"},{"key":"2026061205101439000_14.6.e014890.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.02.005"},{"key":"2026061205101439000_14.6.e014890.36","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"},{"key":"2026061205101439000_14.6.e014890.37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"2026061205101439000_14.6.e014890.38","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1540828"},{"key":"2026061205101439000_14.6.e014890.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-021-07435-2","article-title":"Blinatumomab-induced T cell activation at single cell transcriptome resolution","volume":"22","author":"Huo","year":"2021","journal-title":"BMC Genomics"},{"key":"2026061205101439000_14.6.e014890.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"2026061205101439000_14.6.e014890.41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014043"},{"key":"2026061205101439000_14.6.e014890.42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"2026061205101439000_14.6.e014890.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"2026061205101439000_14.6.e014890.44","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.33298","article-title":"Long-term survival of patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"127","author":"Topp","year":"2021","journal-title":"Cancer"},{"key":"2026061205101439000_14.6.e014890.45","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702555"},{"key":"2026061205101439000_14.6.e014890.46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2026061205101439000_14.6.e014890.47","doi-asserted-by":"publisher","DOI":"10.1038\/nri3212"},{"key":"2026061205101439000_14.6.e014890.48","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1182\/blood.V83.12.3815.3815","article-title":"In vivo blockade of CD28\/CTLA4: B7\/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice","volume":"83","author":"Blazar","year":"1994","journal-title":"Blood"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-014890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:10:28Z","timestamp":1781266228000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-014890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2026-014890"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-014890","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}